Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Airlines Group Inc (AAL) vs Cassava Sciences Inc (FLNA) Price & Performance

American Airlines Group Inc
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

American Airlines Group Inc vs Cassava Sciences Inc — how do they compare? American Airlines Group Inc trades at $16.49 (market cap $11.38B), while Cassava Sciences Inc trades at $1.32 (market cap $63.04M). The key difference: American Airlines Group Inc is far larger — about 180.5× Cassava Sciences Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AALFLNA
Market Cap
$11.38B$63.04M
Sector
IndustrialsHealth
52-Week High
$18.15$4.64
52-Week Low
$10.18$1.16
Enterprise Value
$38.97B-$23.53M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Airlines Group Inc

American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.

Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.

Cassava Sciences Inc

FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.

The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.

Returns comparison

Trailing returns across standard periods

About American Airlines Group Inc

American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

Read more on AAL

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA